Federal contractor · SALISBURY

MINISTRY OF DEFENCE

MINISTRY OF DEFENCE received $4.4M in federal contract obligations in FY2026, on 2 awards (+50% vs FY2025). Since FY2017: $37.3M. Its largest customer was Defense Threat Reduction Agency ($4.4M).

Obligations · FY2026
$4.4M
New awards
2
Sole-source
0.0%
Single offer
100%
UEI
U6LDUQKZ2CS8
Other than small business
Open in the contracts explorerRelationship graph

Company family

Grouped from reported parent companies (UEI) and, where marked, AI judgments that two records name the same organization or group.

Part of the MINISTRY OF DEFENCE company family: 3 registered entities, $4.4M in FY2026 together. See the family

  1. MINISTRY OF DEFENCELIVERPOOL, GBR · Family page
    $0
  2. PORTON BIOPHARMA LIMITEDSALISBURY, GBR
    $0

AI-inferred: entity-match@1 · Analisa AI · 2026-09-30

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 8.6MFY2017
  2. 3.4MFY2018
  3. 7.2MFY2019
  4. 2.5MFY2020
  5. 3.4MFY2021
  6. 339.1KFY2022
  7. 757.2KFY2023
  8. 3.8MFY2024
  9. 2.9MFY2025
  10. 4.4MFY2026

Top buying agencies

Obligations in FY2026.

  1. Defense Threat Reduction Agency$4.4M100%
    2 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

  1. Research & development$4.4M100%

Where the work was performed

  1. Abroad$4.4M100%

Integrity signals

Shares of the year's obligations, next to the country's.

  • Low competition100%
    US 39% · $4.4M
  • Sole-source awards0.0%
    US 30% · $0
  • Single-offer competitions100%
    US 8.7% · $4.4M
  • Urgency justifications0.0%
    US 5.1% · $0

A signal is a reason to look closer, not evidence of wrongdoing: most sole-source awards are lawful and justified.

Largest awards

  1. GENERATION OF A NOVEL ANTIBODY-ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIOIDOSIS OR PLAGUE.$5.6M
    Defense Threat Reduction Agency· Research & development· Jun 6, 2024 – May 18, 2026· HDTRA124C0008
  2. NON IONIC SURFACTANT VESICLES (NISVS) AS A DRUG DELIVERY AND TARGETING SYSTEMS FOR ANTIMICROBIALS$5.5M
    Defense Threat Reduction Agency· Research & development· Sep 28, 2022 – May 19, 2026· HDTRA122C0032

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 2 markets (agency × industry), FY2024–FY2026.

  1. PRIMMUNE THERAPEUTICS, INC.$11.2M−79% in FY2026
    CARLSBAD, CA · 55% of this company's obligations are in markets they both serveDefense Threat Reduction Agency · Scientific research and development services
  2. VITRIVAX, INC.$13.1M+67% in FY2026
    BOULDER, CO · 56% of this company's obligations are in markets they both serveDefense Threat Reduction Agency · Scientific research and development services
  3. AERIS LLC$13.7M−2.9% in FY2026
    LOUISVILLE, CO · 50% of this company's obligations are in markets they both serveDefense Threat Reduction Agency · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026.